Ben D. Markman

246 Clayton Road
Clayton, VIC 3168, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

ISDE guidelines on the management of cT2N0 esophageal cancer.

ISDE guidelines on the management of cT2N0 esophageal cancer.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: January 23, 2026

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 09, 2025

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R.

Durvalumab consolidation after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-R.

Journal: Cancer treatment and research communications

Published: January 02, 2025

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

Journal: ESMO open

Published: November 23, 2023

A gut microbial signature for combination immune checkpoint blockade across cancer types.

A gut microbial signature for combination immune checkpoint blockade across cancer types.

Journal: Nature medicine

Published: June 23, 2023

A tailored approach to horizon scanning for cancer medicines.

A tailored approach to horizon scanning for cancer medicines.

Journal: Journal of cancer policy

Published: April 26, 2023

Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?

Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?

Journal: Cancer

Published: January 24, 2023

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.

Journal: British journal of cancer

Published: January 20, 2023

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 07, 2022

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

Journal: JTO clinical and research reports

Published: August 15, 2022

Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.

Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities.

Journal: Cancers

Published: July 18, 2022

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 10, 2022

Showing 1-12 of 37

Last Updated: 09/26/2026